Efficacy of Antidepressants in Chronic Back Pain

NCT ID: NCT00964886

Last Updated: 2016-11-29

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

142 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-01-31

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This 12 week placebo controlled clinical trial tests the individual and combined effects of an antidepressant medication and cognitive behavioral therapy for chronic back pain.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a 4 arm 12 week randomized clinical trial comparing the efficacy of 1) low concentration desipramine (\< 60 ng/ml); 2) cognitive behavioral therapy; 3) low concentration desipramine + cognitive behavioral therapy; and 4) placebo medication (benzotropine mesylate).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Back Pain

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

chronic pain back pain antidepressants

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm 1

desipramine hydrochloride

Group Type EXPERIMENTAL

desipramine hydrochloride

Intervention Type DRUG

desipramine hydrochloride, with dose targeted to achieve a serum concentration of 5-60ng/ml

Arm 2

cognitive behavioral therapy

Group Type EXPERIMENTAL

cognitive behavioral therapy

Intervention Type BEHAVIORAL

cognitive behavioral therapy, a type of psychotherapy oriented towards restoring function and reducing impact of pain on everyday life

Arm 3

desipramine hydrochloride and cognitive behavioral therapy

Group Type EXPERIMENTAL

desipramine hydrochloride

Intervention Type DRUG

desipramine hydrochloride, with dose targeted to achieve a serum concentration of 5-60ng/ml

cognitive behavioral therapy

Intervention Type BEHAVIORAL

cognitive behavioral therapy, a type of psychotherapy oriented towards restoring function and reducing impact of pain on everyday life

Arm 4

anticholinergic medication; active placebo

Group Type PLACEBO_COMPARATOR

benztropine mesylate 0.125 mg daily

Intervention Type DRUG

benztropine mesylate is a placebo, some of whose side effects mimic those of experimental intervention, desipramine hydrochloride

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

cognitive behavioral therapy

cognitive behavioral therapy, a type of psychotherapy oriented towards restoring function and reducing impact of pain on everyday life

Intervention Type BEHAVIORAL

desipramine hydrochloride

desipramine hydrochloride, with dose targeted to achieve a serum concentration of 5-60ng/ml

Intervention Type DRUG

cognitive behavioral therapy

cognitive behavioral therapy, a type of psychotherapy oriented towards restoring function and reducing impact of pain on everyday life

Intervention Type BEHAVIORAL

benztropine mesylate 0.125 mg daily

benztropine mesylate is a placebo, some of whose side effects mimic those of experimental intervention, desipramine hydrochloride

Intervention Type DRUG

desipramine hydrochloride

desipramine hydrochloride, with dose targeted to achieve a serum concentration of 5-60ng/ml

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Anafranil Cogentin Anafranil

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Chronic back pain (daily pain for \> 6 months)

Exclusion Criteria

* Major medical conditions which might contraindicate antidepressant treatment
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of California, San Diego

OTHER

Sponsor Role collaborator

VA Office of Research and Development

FED

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Joseph H Atkinson, MD

Role: PRINCIPAL_INVESTIGATOR

VA San Diego Healthcare System, San Diego, CA

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

VA San Diego Healthcare System, San Diego, CA

San Diego, California, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Gould HM, Atkinson JH, Chircop-Rollick T, D'Andrea J, Garfin S, Patel SM, Funk SD, Capparelli EV, Penzien DB, Wallace M, Weickgenanta AL, Slater M, Rutledge T. A randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain. Pain. 2020 Jun;161(6):1341-1349. doi: 10.1097/j.pain.0000000000001834.

Reference Type DERIVED
PMID: 32068667 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NURA-019-09S

Identifier Type: -

Identifier Source: org_study_id